ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The latest BCR-ABL-210/ABL was decreased to 0.68% at about 6 months after imatinib was re-initiated, which means an improved response.<h4>Conclusion</h4>The offset effect between CML and SARS-CoV-2 infection was supposed to be the underlying mechanism for the absence of leukocytosis or splenomegaly.